Gall Matthew
- SEC CIK
- 0001816194
No open-market purchases or sales filed in the past year.
Current role at each company
- TNGX Tango Therapeutics, Inc.Chief Financial Officeras of May 5, 2026
- KLRS Kalaris Therapeutics, Inc.Chief Financial Officeras of Mar 20, 2026
- ITOS iTeos Therapeutics, Inc.Chief Financial Officeras of Aug 29, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Gall Matthew as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ITOS iTeos Therapeutics, Inc.
Chief Financial Officer3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 (view filing) | Nov 19 | Same day | Gall MatthewChief Financial Officer | PPurchase | +5.00K | $7.73 | +$38.6K | +8.3%65.4K after | |
| Oct 12, 2023 (view filing) | Oct 12 | Same day | Gall MatthewChief Financial Officer | PPurchase | +5.00K | $8.37 | +$41.9K | +34.7%19.4K after | |
| Dec 28, 2021 (view filing) | Dec 27 | 1 day | Gall MatthewChief Financial Officer | SSale | −5.00K | $46.45 | −$232.3K | −25.7%14.4K after |